DK3827101T3 - Gensignaturer til forudsigelse af melanommetastase og patientprognose - Google Patents

Gensignaturer til forudsigelse af melanommetastase og patientprognose Download PDF

Info

Publication number
DK3827101T3
DK3827101T3 DK19787488.6T DK19787488T DK3827101T3 DK 3827101 T3 DK3827101 T3 DK 3827101T3 DK 19787488 T DK19787488 T DK 19787488T DK 3827101 T3 DK3827101 T3 DK 3827101T3
Authority
DK
Denmark
Prior art keywords
gene signatures
patient prognosis
melanoma metastasis
predict
predict melanoma
Prior art date
Application number
DK19787488.6T
Other languages
Danish (da)
English (en)
Inventor
Alexander Meves
Domenico Bellomo
Original Assignee
Skylinedx B V
Mayo Found Medical Education & Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Skylinedx B V, Mayo Found Medical Education & Res filed Critical Skylinedx B V
Application granted granted Critical
Publication of DK3827101T3 publication Critical patent/DK3827101T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/118Prognosis of disease development
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/166Oligonucleotides used as internal standards, controls or normalisation probes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19787488.6T 2018-07-25 2019-07-25 Gensignaturer til forudsigelse af melanommetastase og patientprognose DK3827101T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862703221P 2018-07-25 2018-07-25
US201862750294P 2018-10-25 2018-10-25
US201862778777P 2018-12-12 2018-12-12
PCT/NL2019/050487 WO2020022895A2 (en) 2018-07-25 2019-07-25 Gene signatures for predicting metastasis of melanoma and patient prognosis

Publications (1)

Publication Number Publication Date
DK3827101T3 true DK3827101T3 (da) 2023-12-11

Family

ID=68242821

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19787488.6T DK3827101T3 (da) 2018-07-25 2019-07-25 Gensignaturer til forudsigelse af melanommetastase og patientprognose

Country Status (11)

Country Link
US (2) US12473599B2 (enExample)
EP (1) EP3827101B1 (enExample)
JP (1) JP7633159B2 (enExample)
KR (1) KR20210044233A (enExample)
CN (1) CN113039289B (enExample)
AU (1) AU2019310636B2 (enExample)
CA (1) CA3107401A1 (enExample)
DK (1) DK3827101T3 (enExample)
ES (1) ES2966015T3 (enExample)
IL (1) IL280377A (enExample)
WO (1) WO2020022895A2 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102751357B1 (ko) * 2021-07-16 2025-01-06 한림대학교 산학협력단 구강암의 임프절 전이 예측과 관련된 유전자군
CA3240376A1 (en) * 2021-12-08 2023-06-15 Alexander MEVES Assessing and treating melanoma
EP4445137A4 (en) * 2021-12-08 2025-12-10 Mayo Found Medical Education & Res MELANOMA ASSESSMENT AND TREATMENT
WO2024108191A1 (en) * 2022-11-18 2024-05-23 University Of Virginia Patent Foundation Machine learning approach to predicting lymph node metastases

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010045A1 (en) 2001-09-07 2004-01-15 Taolin Yi Therapeutic compositions comprised of pentamidine and methods of using same to treat cancer
CA2505416A1 (en) 2002-11-21 2004-06-10 Wyeth Methods for diagnosing rcc and other solid tumors
US20070154889A1 (en) 2004-06-25 2007-07-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060136145A1 (en) 2004-12-20 2006-06-22 Kuo-Jang Kao Universal reference standard for normalization of microarray gene expression profiling data
TW200719903A (en) 2005-04-19 2007-06-01 Combinatorx Inc Compositions for the treatment of neoplasms
NZ593226A (en) 2006-01-11 2012-10-26 Genomic Health Inc Gene expression markers (efnb2) for colorectal cancer prognosis
US8450057B2 (en) 2006-08-14 2013-05-28 The Brigham And Women's Hospital, Inc. Diagnostic tests using gene expression ratios
PT2062049E (pt) 2006-09-06 2014-07-28 Univ California Diagnóstico molecular e classificação de melanoma maligno
EP2152911A4 (en) 2007-05-04 2010-05-19 Dermtech Int DIAGNOSIS OF MELANOMA BY NUCLEIC ACID ANALYSIS
EP2228457A1 (en) 2007-08-16 2010-09-15 Genomic Health, Inc. Gene expression markers of recurrence risk in cancer patients after chemotherapy
CA2716357A1 (en) 2008-03-05 2009-09-11 The Regents Of The University Of California Molecular diagnosis and classification of malignant melanoma
RU2011142806A (ru) 2009-05-01 2013-06-10 ОНКОЗИМ ФАРМА ИНК. (Канада) Комбинации пентамидина для лечения рака
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
EP2619321B1 (en) 2010-09-20 2018-08-01 Advanced Cell Diagnostics, Inc. Biomarkers for differentiating melanoma from benign nevus in the skin
EP3195869B1 (en) 2012-07-27 2021-09-29 Agency for Science, Technology and Research (A*STAR) Method of promoting wound healing
WO2014077915A1 (en) 2012-11-14 2014-05-22 Mayo Foundation For Medical Education And Research Methods and materials for identifying malignant skin lesions
US20170275700A1 (en) 2014-08-14 2017-09-28 Mayo Foundation For Medical Education And Research Methods and materials for identifying metastatic malignant skin lesions and treating skin cancer
KR20250004095A (ko) * 2015-04-17 2025-01-07 브리스톨-마이어스 스큅 컴퍼니 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물
AU2017261688B2 (en) 2016-05-10 2022-09-29 Mayo Foundation For Medical Education And Research Methods and materials for staging and treating skin cancer

Also Published As

Publication number Publication date
US20260071281A1 (en) 2026-03-12
JP2021531831A (ja) 2021-11-25
AU2019310636B2 (en) 2025-06-26
US12473599B2 (en) 2025-11-18
EP3827101A2 (en) 2021-06-02
CN113039289A (zh) 2021-06-25
CA3107401A1 (en) 2020-01-30
ES2966015T3 (es) 2024-04-17
AU2019310636A1 (en) 2021-02-04
NZ771988A (en) 2025-02-28
US20210301353A1 (en) 2021-09-30
WO2020022895A3 (en) 2020-04-02
JP7633159B2 (ja) 2025-02-19
EP3827101B1 (en) 2023-11-08
IL280377A (en) 2021-03-25
WO2020022895A2 (en) 2020-01-30
KR20210044233A (ko) 2021-04-22
CN113039289B (zh) 2025-11-07

Similar Documents

Publication Publication Date Title
IL267797A (en) Anti-gpc3 antibody
DK3507386T3 (da) Fremgangsmåder og indretning, der øger effektiviteten af sekvensering med binding
DK3436048T3 (da) Neoantigener og fremgangsmåder til anvendelse deraf
DK3827101T3 (da) Gensignaturer til forudsigelse af melanommetastase og patientprognose
DK3454844T3 (da) Behandling af tyktarmskræft med en kombination af hdac-inhibitoren hbi-8000 og en pd-l1-inhibitor
DK3797182T3 (da) Elektrolyseenhed og fremgangsmåde til drift af elektrolyseenhed
DK3153398T3 (da) Flydende struktur og fremgangsmåde til installation heraf
DK3553180T3 (da) Fremgangsmåde til konstruktion af enkeltcellesekventeringsbibliotek og anvendelse deraf
DK3103046T3 (da) Biomarkør-signaturfremgangsmåde og apparater og kits deraf
DK3350220T3 (da) Anti-pro/latente-myostatin-antistoffer og anvendelser deraf
DK3202915T3 (da) Anvendelse af cellefri dna-fragmentstørrelse til at bestemme kopiantalvariationer
DK3820906T3 (da) Multispecifikke wnt-surrogatmolekyler og anvendelser deraf
DK3012329T3 (da) Fremgangsmåder og materialer til at vurdere tab af heterozygositet
DK3433273T3 (da) Binding af molekyler til cd38 og pd-l1
DK3318001T3 (da) Fremgangsmåder og indretninger til håndtering af hash-tree-baserede datasignaturer
EP3867405A4 (en) EPIGENETIC BIOMARKER AND USES THEREOF
DK3607065T5 (da) Fremgangsmåde og kit til konstruktion af nukleinsyrebibliotek
DK3595665T3 (da) Dobbelthæmmere af magl og faah
DK3215598T3 (da) Fremgangsmåde til drift af en røreindretning og en forgasningsbeholder
EP3732816C0 (en) SECURE INSTALLATION OF APPLICATION KEYS
DK3170784T3 (da) Fremgangsmåde til drift af et ankerspil og ankerspil
EP3765610A4 (en) MICRO-RNA AND OBESITY
DK3396024T3 (da) Elektrokemisk anordning og fremgangsmåde til drift af en elektrokemisk anordning
DK3130721T3 (da) Flerlagsrenoveringsbygningselement og udvendig overflade på bygning
DK3423636T3 (da) Transportabelt stormflodsdæmningssystem og anvendelser heraf